In the field of lung cancer diagnosis and treatment, genetic testing of lung percutaneous biopsy samples is mainly used to evaluate the value of targeted drug use, such as detecting gene mutations such as EGFR and K-RAS. This evidence concerns the gene KRAS and lung cancer.